Skip to main content
. 2022 Sep 22;35(11):2122–2132. doi: 10.1021/acs.chemrestox.2c00231

Figure 6.

Figure 6

LC–MS/MS characterization of HSA adducts formed by tazobactam and clavulanate in vitro. Representative MS/MS spectrum of the albumin peptide 182LDELRDEGKASSAK195 modified at Lys190 with clavulanate (A). A similar adduct was also formed by tazobactam (B). The epitope map on HSA shows the lysine residues modified by tazobactam (at drug/protein molar ratio 100:1) or clavulanate (at drug/protein molar ratio 20:1); residues modified by both compounds are highlighted in pink and additional residues modified only by clavulanate are highlighted in green. Images are illustrated by PyMOL (The PyMOL Molecular Graphics System, Version 1.3 Schrödinger, LLC). The level of modification with clavulanate and tazobactam is concentration-dependent (D,E). (F) Summary of the HSA lysine residues targeted by clavulanate and tazobactam and the nature of the adducts formed.